Search
Econazole
go.drugbank.com/drugs/DB01127ApprovedA broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.
Mixtures: PM ExternalCategories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2E1 InhibitorsZolazepam
go.drugbank.com/drugs/DB11555ExperimentalVet approvedIt is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that its onset is very fast.
Rozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigationalRozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB.
RO7284755
go.drugbank.com/drugs/DB17527InvestigationalRO7284755 is an investigational cancer drug: it is a PD-1-targeted IL-2 variant antibody fusion protein.
Dyclonine
go.drugbank.com/drugs/DB00645ApprovedInvestigationalDyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It may also be found in some Cepacol sore throat spray products.
Synonyms: 2-(1-piperidyl)ethyl p-butoxyphenyl ketoneMixtures: Tanac Medicated GelBoric acid
go.drugbank.com/drugs/DB11326ApprovedInvestigationalBoric acid, also known as hydrogen borate, is a weak monobasic Lewis acid of boron with the chemical formula H3BO3. Boric acid is typically utilized in industrial processing and manufacturing, but is also used as an additive in pharmaceu...
Mixtures: ICEKING Skin Expert Anti-onychomycosis GelZanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigationalZanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell n...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLedaborbactam etzadroxil
go.drugbank.com/drugs/DB21455InvestigationalLedaborbactam etzadroxil is under investigation in clinical trial NCT06733675 (Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination).
Ancremonam
go.drugbank.com/drugs/DB19710InvestigationalAncremonam is under investigation in clinical trial NCT03377426 (LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)).
Enlonstobart
go.drugbank.com/drugs/DB21890Investigational[A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.